
    
      This is a Phase 3, open label, multi-centre, study for patients requiring Ig replacement
      therapy. This study is a follow-on study to patients who have completed the CSLCT-SCIG-05-23
      clinical trial and wish to continue subcutaneous treatment with Ig NextGen 16% .
      Additionally, patients currently receiving IVIg with unacceptable adverse reactions or unable
      to tolerate IVIg as well as patients receiving alternate IG products via the SC route may be
      enrolled in this study. Patients must not be eligible for any of the Sponsor's ongoing PID
      studies that are still open to enrolment.
    
  